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Abstract: Feline infectious peritonitis (FIP) caused by feline coronavirus (FCoV) is a common dis-ease
in cats, fatal if untreated, and no effective treatment is currently legally available. The aim of this
study was to evaluate efficacy and toxicity of the multi-component drug Xraphconn® in vitro and as
oral treatment in cats with spontaneous FIP by examining survival rate, development of clinical and
laboratory parameters, viral loads, anti-FCoV antibodies, and adverse effects. Mass spectrometry and
nuclear magnetic resonance identified GS-441524 as an active component of Xraphconn®. Eighteen
cats with FIP were prospectively followed up while being treated orally for 84 days. Values of key
parameters on each examination day were compared to values before treatment initiation using
linear mixed-effect models. Xraphconn® displayed high virucidal activity in cell culture. All cats
recovered with dramatic improvement of clinical and laboratory parameters and massive reduction
in viral loads within the first few days of treatment without serious adverse effects. Oral treatment
with Xraphconn® containing GS-441524 was highly effective for FIP without causing serious adverse
effects. This drug is an excellent option for the oral treatment of FIP and should be trialed as potential
effective treatment option for other severe coronavirus-associated diseases across species.
Keywords: FIP; feline coronavirus; FCoV; treatment; therapy; antiviral chemotherapy; Xraphconn®;
GS-441524; Mutian
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1. Introduction
Coronaviruses comprise a large family of RNA viruses that infect a wide variety of
mammalian and avian hosts, causing severe disease in some of them [1–3]. Their high
diversity causes the continuous emergence of new coronavirus variants that can have
changed target cell tropism and/or host spectrum and lead to interspecies or zoonotic
transmission; recent examples of the latter are Severe Acute Respiratory Syndrome Coron-
avirus (SARS-CoV), Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and
the most recent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) causing
Coronavirus Infectious Disease 2019 (COVID-19) [4–7]. The newly emerging coronavirus-
associated diseases raise awareness of the potential risks of highly virulent coronavirus
infections in humans with close contact to animals harboring coronaviruses [8]. Shifts in
tissue or cell tropism resulting in changes in virulence are distinctive features of coron-
aviruses. The best prototypic example for such a virulence change is the feline coronavirus
(FCoV), which occurs as two different biotypes [9–12]. Only a small proportion (7–14% in
multi-cat environments) of cats infected with FCoV, which is very common among multi-
cat populations, develops the fatal disease feline infectious peritonitis (FIP) [13], triggered
by spontaneous mutation of FCoV, thus gaining tropism for monocytes/macrophages
in individual cats [14–19]. All cats with FIP either die or have to be euthanized without
availability of effective treatment. The median survival time of untreated cats is only eight
to nine days [9,20]. Previous controlled treatment trials with antiviral compounds either
showed limited efficacy, such as the use of feline interferon-omega [9], or were too toxic
for cats, such as ribavirin [21–23]. In most countries, such as in Europe and the United
States, there is currently no effective licensed treatment option for cats with FIP, although
unlicensed compounds have been imported and used by cat owners. It is important that
veterinarians consult their local regulations and laws before embarking on the use of any
unlicensed antiviral agents for the treatment of FIP due to variation in laws governing the
veterinary profession and veterinary medicines worldwide.
However, a few studies have been published recently in which compounds not yet
licensed showed extraordinarily promising results [24–27]. The most recent promising
treatment for cats with FIP is the use of the nucleoside analogue GS-441524 [24,25,28],
which is the active form of the prodrug remdesivir [29]. Currently, remdesivir is only
conditionally licensed to treat human patients with severe COVID-19 symptoms [30–32].
Cats in these prospective studies received GS-441524 subcutaneously for various time
periods and owners were instructed by social media groups to inject the compounds
likewise for a period of 12 weeks or longer. Subcutaneous injections over such a long time
period are difficult to perform by owners, can be very painful for cats due to the low pH of
these unlicensed and uncontrolled preparations, and moreover could be associated with
feline injection site sarcomas (FISS) [33]. Thus, oral compounds would be advantageous.
Indeed, one case of successful treatment of a single cat with FIP (showing ocular signs but
no effusion) with an oral preparation called Mutian (Mutian 200, Nantong Biotechnology,
Nantong, China) has been reported [26]. Mutian was administered orally every 24 h
(q24h) for 50 days and the cat received additional symptomatic treatment as well as feline
interferon-omega. Within a few weeks of treatment, the cat showed marked gain in
body weight and improvement of ocular signs as well as hematological and biochemical
parameters. In two recent retrospective studies, cats were also treated with oral antivirals.
In one, a large-scale online survey was addressed to cat owners who treated their cats
with suspected FIP with an antiviral drug to collect their experiences, e.g., improvement
of symptoms, potential relapses, and supportive therapy during the treatment [34]. In
the other retrospective study from China, the disease course of 127 cats with suspected
FIP was followed up; of these, 24 were treated with GS-441524 (although the route of
administration was not mentioned) and only one cat relapsed [35]. However, to the authors’
knowledge, there are no published prospective studies on the oral treatment of cats with
highly suspected or confirmed FIP with antiviral compounds. If the efficacy of an oral
treatment in cats with a deadly disease like FIP could be consistently proven, this could
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also open up new avenues for future research investigating its effect in other severe corona-
virus-associated diseases, such as COVID-19. Furthermore, due to its similarities of clinical
features, the FIP-cat model could serve as natural model for elucidating pathophysiological
features and potential treatment approaches in severe systemic inflammatory coronavirus-
associated syndromes [6].
Therefore, the aim of this study was to prospectively evaluate the efficacy of an oral
multi-component drug, first in vitro and then as oral treatment, in cats with naturally
occurring FIP in a clinical trial, by determining survival rate, improvement of clinical and
laboratory parameters, reduction of viral loads, and measurement of anti-FCoV antibodies.
Additionally, potential adverse effects were recorded and the chemical structure of the
active ingredient within the multi-component drug was identified by means of structural
chemistry analysis.
2. Materials and Methods
2.1. Compound
The compound Xraphconn® was used for the in vitro study as well as in the cats.
It was provided by Mutian Life Sciences Limited in 2 batches (Supplementary File S1).
According to the tablet insert, the active ingredient (referred to as MT-0901 in the package
insert) was available at a concentration of 2.5 mg or 10 mg tablet, respectively. Other
ingredients according to the tablet inserts were, among other substances, Radix scro-
phulariae, Platycodon grandiflorum, Phyllostachys pubescens, Forsythia suspensa, and
Anemarrhena asphodeloides.
2.2. In Vitro Efficacy of the Multi-Component Drug
Efficacy of Xraphconn® was first evaluated in an established cell culture model.
Crandell-Rees Feline Kidney (CRFK) cells (Collection of Cell Lines in Veterinary Medicine
CCLV, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany) were grown and
maintained in Eagle’s minimal essential medium (MEM; Biochrom, Berlin, Germany) sup-
plemented with 10% fetal calf serum (FCS; Biochrom) and kept at 37 ± 1 ◦C under a 5% CO2
atmosphere. Feline coronavirus RVB-1259 (a serotype I FCoV strain) was propagated once
in CRFK cells in MEM as described above.
For the application on cells, a tablet (50 mg) said to contian 2.5 mg of the active
ingredient was crushed using a mortar and 5 mL MEM or dimethyl sulfoxide (DMSO)
was added. Suspensions were cleared by syringe filtration (Millex-GP syringe filter, pore
size 0.22 µm). Subsequently, a logarithmic dilution was performed with both suspensions
(1:10 up to 1:100,000), mathematically corresponding to an active ingredient concentration
ranging from 50 µg/mL to 5 ng/mL at the assumption that the yield of extraction was 100%.
After exposure of the cells to the different dilutions of the filtrated tablet suspension, cell
viability measurement using an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide, a tetrazole) assay (Cell Proliferation Kit; Roche, Basel, Switzerland) was per-
formed. Briefly, CRFK cells were seeded on a 96-well plate and different compound
dilutions were added after 24 h. Cells were incubated for another 24 or 48 h, respectively.
Subsequently, 10 µL MTT was added and cells were incubated for another 4 h. After
incubation, solubilization solution was added and the enzymatic reaction was measured
spectrophotometrically on the next day.
To evaluate the efficacy of Xraphconn® in vitro, CRFK overnight cell cultures were
infected with FCoV at a multiplicity of infection (MOI) of 0.01. After infection, wells were
incubated at 37 ± 1 ◦C under a 5% CO2 atmosphere for 60 min and then washed with
phosphate-buffered saline (PBS). Fresh culture medium (MEM supplemented with 5% FCS)
containing different Xraphconn® dilution levels was added. Finally, supernatants were col-
lected at 24 or 48 h post infection. All tests were carried out as quadruplicate measurements.
Total RNA was extracted from all supernatants using the Nucleo-MagVet kit (Macherey-
Nagel, Düren, Germany) according to the manufacturer’s instructions in an elution volume
of 100 µL. Feline coronavirus RNA was detected by reverse transcriptase polymerase chain
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reaction (RT-PCR) as described below. To calculate the half maximal effective concentration
(EC50), the viral RNA load for virus-infected non-treated cells was set to 100% and RNA
values obtained for treated cells were normalized to this value; EC50-values were calcu-
lated by a non-linear regression analysis using GraphPad Prism 9.0 (GraphPad Software,
San Diego, CA, USA).
2.3. Patients of the Prospective In Vivo Study
This study complied with the German guidelines for prospective studies and was
approved by the Government of Upper Bavaria (reference number 55.2-2532.Vet_02-20-52)
and by the ethical committee (reference number 261-19-03-2021) of the Centre for Clinical
Veterinary Medicine of the LMU Munich. In addition, owners of the cats also gave their
written consent to participate. Twenty cats were originally enrolled in the study (Figure 1).
Inclusion criteria were (1) diagnosis of FIP, (2) body weight of at least 2 kg, (3) negative
test results for feline immunodeficiency virus (FIV) and feline leukemia virus (FeLV)
infection, and (4) absence of other severe diseases. Cats were excluded if (1) they were in a
severe moribund or comatose condition at the time of presentation (as in such condition
oral medications cannot be expected to be reliably absorbed), (2) it was not possible to
administer tablets to the cats, or (3) owners were not compliant to either medicate their
cats properly or to attend appointments.
chereyNagel, Düren, Germany) according to the manufacturer’s instructions in an elution 
Figure 1. Flow diagram illustrating enrollment, inclusion, allocation process to high-dose treatment
(10 mg/kg) for cats with neurological/ocular signs or low-dose treatment (5 mg/kg) for cats without
neurological/ocular signs (based on the package inserts, Supplementary File S1), and outcome of
cats in the study.
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A diagnosis of FIP was made (Table 1) if (1) virus was detected directly, either by im-
munohistochemistry detecting FCoV antigen within macrophages of altered organs [36,37]
and/or by detection of a mutated strain of FCoV in effusion, blood, or an organ fine needle
aspirate by a commercial RT-PCR and analysis targeting FCoV spike gene mutations lead-
ing to spike protein substitutions M1058L and S1060A (IDEXX laboratories, Ludwigsburg,
Germany) in combination with (2) clinical and clinicopathological abnormalities considered
typical for FIP [38] being present in the cats. Body weight was measured using a baby
scale (AE Adam MTB 20 baby scale, Felde, Germany). The weight limit was set at 2 kg to
comply with guidelines for blood volume sampling in cats according to the Gesellschaft
für Versuchstierkunde—Society of Laboratory Animal Science [39]. Presence of anti-FIV
antibodies and FeLV antigen was tested by the referring veterinarian or at presentation
with either a point-of-care test or at a commercial laboratory. Absence of other severe
diseases was determined by obtaining a complete history and physical examination as well
as by performing an abdominal ultrasound in all cats on the day of entering the study;
in addition, echocardiography was performed in cats with a thoracic effusion and a full
neurological examination was performed in cats with neurological signs. Presence of mild
disease (such as intestinal parasite infestation, otitis externa, rhinitis, chronic gingivostom-
atitis) did not lead to exclusion (Table 1). One cat had mild renal azotemia at the time of
inclusion (Table 1). It was reasonable to suspect that these renal changes were caused by FIP
and therefore the cat was included in the study. Of the 20 cats that were originally enrolled
into the study, two cats were subsequently excluded due to their severe moribund health
condition (Figure 1). Thus, 18 cats finally entered the study. Cats were then allocated to
either high-dose treatment (10 mg/kg) if they had neurological/ocular (n = 2) or low-dose
treatment (5 mg/kg) if they had no neurological/ocular signs (n = 16).
The age of the 18 cats (Table 1) ranged between 4.7 and 56.5 months (median 7.7 months)
and 15 cats (83.3%) were younger than one year. Most cats (11/18; 61.1%) were European
Shorthair (ESH); the others belonged to different breeds. The majority of cats was male
(12/18; 66.6%) with 5 of them neutered. Of the female cats (6/18; 33.3%), 3 were neutered.
2.4. In Vivo Study Design
Cats were treated orally with Xraphconn® for 84 days (day 0 to day 83). The dosage
of the compound was chosen based on described studies with GS-441524 [24,28] and was
based on the information of the tablet package insert on the concentration of the active
component in the tablet. Thus, cats were treated with 5 mg/kg of the active component per
os (PO) q24h if they had no neurological and/or ocular signs and at 10 mg/kg PO q24h if
they had neurological and/or ocular signs. Dosage of Xraphconn® tablets was adjusted
daily to the determined weight and tablets were always administered at the same time on
an empty stomach. Half an hour after tablet administration, food was provided to the cats.
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Table 1. Cats participating in the study, including signalment, number of additional cats in the household, method of diagnosis of feline infectious peritonitis (FIP), FIP-associated signs,






























































































































































































































































































































































































































































































































mg, milligram; kg, kilogram; q24h, every 24 h; ESH, European shorthair; RT-PCR, reverse transcription polymerase chain reaction; S, spike; BSH, British shorthair; spp., species. 1 diagnosis of FIP: FIP confirmed:
positive IHC plus consistent histopathology; FIP very likely: positive RT-PCR and analysis for FCoV spike mutation. 2 end: until the end of the observation period. 3 fluid therapy with Ringer’s lactate with
potassium supplementation at 20 mval/L for dehydration at an individual dosage calculated by rehydration and maintenance needs. 4 metamizole 30 mg/kg intravenously (IV) for treatment of fever (body
temperature > 40.5 ◦C) as a single injection. 5 antibiotics (i.e., amoxicillin/clavulanic acid 20 mg/kg q8h IV or per os (PO); trimethoprim sulfadiazin 20 mg/kg q12h IV or PO; marbofloxacin 2 mg/kg q24h
IV; pradofloxacin 6 mg/kg q24h PO; ampicillin 12.5 mg/kg q8h IV for treatment of secondary suspected or proven bacterial infection (neutrophilia with left shift or continuously high body temperature).
6 buprenorphine 0.01 mg/kg q8h IV for treatment of pain. 7 maropitant 1 mg/kg q24h IV for treatment of gastrointestinal signs, such as vomiting and anorexia. 8 mirtazapine ointment q24h for appetite
stimulation. 9 silymarin 20 mg/kg q12h PO for 10 days and then 20 mg/kg q24h PO for treatment of increased liver enzymes. 10 oxygen cage for support in cases of dyspnea in cats with massive thoracic effusion.
11 pregabalin 2 mg/kg q12h PO when buprenorphine was not sufficient to control pain. 12 meloxicam 0.1 mg/kg q24h PO for 1 day and then 0.05 mg/kg q24h PO for treatment of orthopedic pain.
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All cats were hospitalized for the first 8 days (day 0 to day 7). During this time,
cats were under intensive surveillance and medical care by board-certified specialists
in internal medicine and intensive care for 24 h per day, and all diagnostic procedures,
supportive measures, and symptomatic treatments were applied as necessary (Table 1). On
day 0, before treatment with Xraphconn®, a history and complete physical examination
as well as hematological and clinical chemistry parameters were obtained in each cat.
Several parameters were evaluated during the first 8 days and at several time points
during the rest of the treatment period (Table S1). This included physical examination
(including measurement of body weight and determination of the modified Karnofsky’s
score (Table S2) (day 0, 1, 2, 3, 4, 5, 6, 7, 14, 28, 56, 83), abdominal ultrasound (day 0, 4, 7,
14, 28, 56, 83), hematology and clinical chemistry (including symmetric dimethylarginine
(SDMA) and serum amyloid A (SAA)) (day 0, 2, 4, 7, 14, 28, 56, 83), and measurement
of blood viral load (day 0, 2, 4, 7, 14, 28, 56, 83), effusion viral load (in case of effusion
accessible for drainage), and serum anti-FCoV antibodies (day 0, 7, 14, 28, 56, 83). As long
as the cats had abdominal or thoracic effusions, abdominal or thoracic ultrasound and
if possible abdominocentesis or thoracocentesis, respectively, were performed daily, and
fluid was stored for determination of viral load.
The Karnofsky’s score modified for cats by Hartmann and Kuffer (1998) was used to
evaluate the general condition and well-being of the cats (Table S2) using a classification
from 0% (dead) to 50% (normal health condition) [40,41]. Hematology was performed
using an automatic analyzer (Cell-Dyn 3500, Abott Laboratories, IL, USA). Differential
blood count was additionally performed manually on blood smears exposed to Haema
Quick Staining/Diff-Quick staining if hematology parameters were abnormal. Serum
biochemistry parameters were measured by an automatic analyzer (Hitachi 911, Roche,
Grenzach-Wyhlen, Germany), SDMA was analyzed at IDEXX Diavet AG (Bäch, Switzer-
land) using a high-throughput immunoassay, and SAA was determined using a latex
agglutination turbidimetric immunoassay reaction (LZ Test SAA, Eiken Chemical Co.,
Ltd., Tokyo, Japan) on a cobas® c 501 clinical chemistry analyzer (Roche Diagnostics AG,
Rotkreuz, Switzerland).
Cats were discharged on day 7 (unless clinical condition required prolonged inpatient
care), and owners continued daily administration of the study drug. Owners received
personalized instructions, including videos, on how to administer the tablets. They were
instructed to call in at any time in case of problems. For the remaining period, owners had
to closely monitor their cats at home and remain in close contact with the study team. Cats
were not allowed outdoors during the treatment period. However, 17/18 cats had between
1 and 9 partner cats (most of which were allowed to go outside) in the same household
with close contact (Table 1). Owners had to keep a daily diary for recording their cats’
clinical parameters and body weight to guarantee optimal drug dosing at all times.
2.5. FCoV Viral Load in Blood and Effusion
Feline coronavirus RNA load was determined on several days in blood and effusion
samples (as long as present). Samples were stored at −80 ◦C and analyzed collectively
by RT-quantitative PCR (RT-qPCR). Viral total nucleic acids (TNA) were extracted from
200 µL of effusion or 100 µL ethylenediaminetetraacetic acid (EDTA) anticoagulated whole
blood using the MagNa Pure 96 (Roche Diagnostics AG, Rotkreuz, Switzerland) and
the MagNA Pure 96 DNA and Viral NA SV Kit (Roche Diagnostics AG, Risch-Rotkreuz,
Switzerland) according to the manufacturers’ instructions with an elution volume of
100 µL. For all samples, the viral nucleic acid (NA) plasma external lysis SV 4.0 protocol
was applied. For each batch of extractions, negative controls were run in parallel to check
for cross-contamination.
A previously published RT-qPCR assay was used to detect the FCoV 7b gene [42].
The methods were adapted as follows: primer and probes [42] were used with the
AgPath-IDTM One-step RT-PCR kit (Applied Biosystems, Rotkreuz, Switzerland). The
mastermix consisted of 1X RT-PCR buffer, 1.0 µL Array Script reverse transcriptase and
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AmpliTaq Gold DNA polymerase, 300 nM forward primer (FCoV2), 900 nM reverse primer
(FCoV1), 300 nM probe (FCoVp), and nuclease-free H2O was added to a final volume of
20 µL. All RT-qPCR assays were run with 5 µL of TNA in a final volume of 25 µL. Positive
and negative controls were run in parallel using a ABI 7500 Fast instrument (Applied
Biosystems). All samples were tested for absence of inhibition. A FCoV RNA standard
curve was run in parallel to determine the viral RNA copy number.
2.6. Anti-FCoV Antibodies
Antibodies against FCoV were measured on days 0, 7, 14, 28, 56, 83. Serum samples
were stored at −80 ◦C and analyzed by an indirect immunofluorescence assay (IFA) as
previously described [43–46]. Briefly, cat samples were tested at dilutions of 1:25, 1:100,
1:400, 1:1600, and 1:6400. The fluorescein isothiocyanate (FITC) conjugated secondary
antibody (rabbit anti cat IgG (H + L) (Nordic-MUbio, Sustern, Netherlands; LuBio Sience
GmBH, Luzern, Switzerland) was diluted at 1:40. Slides were prepared using porcine
kidney cells (PD-5 cells) infected with transmissible gastroenteritis virus (TGEV, Purdue
strain). The antigen preparations were tested for the absence of contaminating viruses
by RT-qPCR and qPCR as previously described [45]. A positive control (aliquoted serum
sample of a FCoV-antibody-positive field cat) and a negative control (aliquoted serum from
a specific pathogen free FCoV-antibody-negative cat) were run with each slide.
2.7. Characterization of the Active Ingredient in the Multi-Component Drug
Characterization of the active ingredient was performed by mass spectrometry (MS)
and nuclear magnetic resonance (NMR). For details regarding these analyses, refer to the
supporting information (Supplementary Text S1).
2.8. Data Analysis
Data were analyzed using R statistical language (version 4.0.3; R Core Team, 2020).
Due to the repeated measures for an individual animal on multiple days, all variables were
evaluated using linear mixed-effects models, with an individual animal as a random effect.
The following model assumptions were always checked: (1) the normality of residuals
was evaluated by the Shapiro–Wilk normality test, (2) the homogeneity of variances was
evaluated with Levene’s test, (3) the heteroscedasticity (constancy of error variance) was
evaluated with Breusch-Pagan test. In case assumptions were violated, a robust linear
mixed-effects regression (RLMER) was applied; RLMER computes weighted estimates
via Design Adaptive Scale approach and thus, solves heteroskedastic and non-normally
distributed residuals by assigning lower weights to outliers and other contaminations. All
contrasts (differences) between particular days were assessed after model-fitting by the
estimated least-squares marginal means with the Bonferroni p-value correction for multiple
comparisons. For comparison of the number of cats with effusion per day, pairwise Fisher’s
tests were performed also with the Bonferroni p-value adjustment for multiple testing.
Results with a p-value ≤ 0.05 were considered statistically significant. A nonparametric
bootstrap with replacements that does not assume normality was used for obtaining and
visualizing means and 95% confidence limits of blood and effusion viral loads.
3. Results
3.1. Efficacy of the Multi-Component Drug In Vitro
The cytotoxic effect of the multi-component drug Xraphconn® solubilized in MEM or
DMSO was examined on CRFK cells using an MTT assay. After 24 and 48 h of treatment, the
Xraphconn® solution exhibited no major cytotoxicity at a dilution of 1:100, independent of
the applied solvent. Therefore, Xraphconn® solubilized in MEM at 1:100 and successive log
dilutions were used for the antiviral efficacy testing. For this purpose, FCoV (MOI of 0.01)
replication in Xraphconn®-treated and non-treated CRFK cells was measured by RT-qPCR,
and FCoV replication inhibition by Xraphconn® (concentration 1:100) was significant, as
viral RNA levels in treated cells were drastically reduced compared to the non-treated
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controls. This dilution corresponds to a concentration of 5 µg/mL of the active compound
in the solution. For FCoV-infected CRFK cells, the calculated EC50-value of the Xraphconn
®
solution was 1.65 µg/mL (Figure 2).
wise Fisher’s tests were performed also with the Bonferroni 
value ≤
 
were determined by the Bonferroni’s multiple comparisons test and are indicated as follows: ≤
Figure 2. Feline coronavirus (FCoV) replication inhibition by Xraphconn®. (A) FCoV cycle thresh-
old (ct) values in supernatants collected from infected Crandell-Rees Feline Kidney (CRFK) cells
(multiplicity of infection (MOI = 0.01) treated with the indicated active compound concentrations
were collected at 24 h post infection (n = 4). Significance levels compared to the results for untreated
cells were determined by the Bonferroni’s multiple comparisons test and are indicated as follows:
*, p ≤ 0.05; ****, p < 0.0001. (B) Data from four biological replicates were used to calculate the half
maximal effective concentration (EC50) value by non-linear regression analysis.
3.2. Efficacy of the Multi-Component Drug in Cats With FIP
All 18 cats completely recovered clinically within the 84 days of treatment. No relapse
occurred, and at the time of publication (99 days after the last cat had finished its treatment
course), all cats were still alive. With one exception, all cats were healthy and asymptomatic
at the end of the treatment period. The only cat that showed any clinical signs at the end of
treatment, as well as at the time of publication, was the cat presenting with renal azotemia
at time of inclusion in the study (cat 3). This cat recovered clinically from all other signs
related to FIP, but developed unilateral renal mineralization, which was first observed on
day 21 of treatment. Renal azotemia improved with fluid therapy and overall remained
stable during the treatment period. On day 168, three months after the end of treatment,
the cat had developed unilateral ureteral obstruction with hydronephrosis and mild ascites,
which most likely occurred secondary to the obstruction and was unrelated to FIP.
In all treated cats, clinical and laboratory parameters improved constantly and signifi-
cantly during the treatment (Figures 3, Figure 4, Figure 5 and S1). Of the 18 cats, 17 were
discharged from the hospital after the first 7 seven days with a modified Karnofsky’s score
of at least 45% (with 50% being equivalent to completely healthy) (Figure 3A); one cat had
to stay hospitalized for 11 days due to the development of pyothorax. All cats gained
body weight rapidly (Figure 3B) and had normal body temperatures soon after treatment
initiation (Figure 3C) and the amount of effusion decreased markedly (Figure 3D), as did
the number of cats that still had effusion (Figure S1). In addition, all clinicopathological
parameters (hematological and clinical chemistry parameters including SAA) improved
steadily (Figure 4A–H) with significant differences in the parameters by day 1 to day 28
when compared to day 0 (before treatment). Remarkably, in most of the cats (15/18), viral
RNA could be detected in blood before treatment, but blood viral loads decreased massively
in all cats by day two to four after treatment initiation (Figures 5A and 6A). By day 14,
viral RNA was no longer detected in the blood of the cats (Figures 5A and 6A), indicating
that all had cleared detectable viremia. All accessible effusions tested RT-qPCR-positive
at the start of the study (Figures 5B and 6B). Later on, viral RNA was detectable in all but
three effusion samples (Figure 5B). However, these three cats had smaller volumes of effu-
sion collected and evaluated by RT-qPCR. All cats had serum anti-FCoV antibodies at the
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initiation of the study, most of them with high antibody titers (14/18 with titers ≥1:1600).
Anti-FCoV antibody titers declined in 14/18 cats, in some cats starting as early as 28 days
after the initiation of treatment (Figures 5C and S2). In none of the cats was an antibody
titer increase observed.
3.3. Adverse Effects of the Multi-Comoonent Drug in Cats
No serious adverse effects were observed during Xraphconn® treatment (Table 2) and
therefore in none of the cats did treatment have to be discontinued. Mild Heinz body
anemia (with 19.8% of red blood cells containing Heinz bodies, hematocrit 32.5% (reference
range: 33–44%)) was observed in one cat on the last day of the Xraphconn® treatment
(day 83). The cat was treated with S-adenosyl-methionine (Table 1) and the hematocrit
normalized (to 34.7% on day 100) and Heinz bodies decreased (to 8.8% on day 126). Lym-
phocytosis was seen in 14/18 (77.7%) cats; three of those already had moderate, and two
of those severe, lymphocytosis before treatment initiation (Table 2). In most of the cats,
however, lymphocytosis was only mild to moderate. One cat (before treatment, the cat
had a lymphocyte count at the lower end of the reference range (1.1 × 109/L)), however,
developed a massive lymphocytosis on day 83 (40.7 × 109/L). Cytology of a blood smear
revealed a high number of predominantly small lymphocytes, isolated large or reactive
lymphocytes with dark blue cytoplasm. To rule out chronic lymphocytic leukemia, a
PCR for Antigen Receptor Rearrangements (PARR) analysis was performed, which was
consistent with a reactive lymphoid cell population. The majority of cats (11/18; 61.1%)
developed eosinophilia during the treatment period, but in all cats this was only mild
(<2.0 × 109/L). Fecal examinations were performed in 10/11 cats with eosinophilia to
exclude parasite infestation. In one cat, Giardia spp. infection was present before start of the
Xraphconn® treatment, and the cat was treated with fenbendazole; in another cat, Giardia
spp. infection was detected by fecal examination on day 56 (this cat had no eosinophilia;
fecal examination was performed because the partner cat suffered from Giardia spp. in-
fection). An increase in liver enzyme activity was noted in 11/18 cats between day 2 and
day 83, but was mostly only mild to moderate. An increase of alanine aminotransferase
(ALT) activity was observed in 7/18 (38.9%) cats; of those, two cats had a severe ALT
activity increase and were treated with silymarin. An increase in alkaline phosphatase
was seen in 8/18 cats, but was only mild (seven cats) to moderate (one cat). No renal
toxicity was detected. With one exception, SDMA remained within the reference range
throughout the whole treatment period. One cat had renal azotemia, which was already
present before treatment initiation with increased creatinine, urea, and SDMA. None of
the cats developed azotemia or showed an increase in creatinine of more than 26.4 µmol/L
in the non-azotemic range within 48 h and none of the cats developed oliguria, and thus,
there was no evidence of acute renal toxicity [47]. Mild prerenal azotemia (with isolated
urea concentration elevation between 11.6–12.7 mmol/L) was detected in four cats, but
those cats had not been fasted before blood sampling.
3.4. Characterization of the Main Active Ingredient in the Multi-Component Drug
Evaluation of the structure of the active component in Xraphconn® by Ultra-High-
Performance-Liquid Chromatography Electro-Spray QTRAP Mass Spectrometry (UHPLC-
ESI-QTRAP-MS/MS) using Multiple Reaction Monitoring with Information Dependent
Acquisition and Enhanced Product Ion Scan (MRM-IDA-EPI scan) provided a MS/MS
fragment pattern that was practically identical to that of a control measurement performed
with GS-441524 (Figure 7).
As LC-MS/MS could not distinguish between a furanose ring of GS-441524 and a
pyranose ring and a ring opening during collision-induced decay (CID) would provide very
similar MS-fragmentation patterns of the two compounds, further structure elucidation
could only be performed via NMR spectroscopy.
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Figure 3. Timeline visualizing improvement of clinical parameters throughout the study course.
Figures show average predictive values and 95% confidence intervals of each parameter. Grey
shading marks the reference ranges of the parameters. Red asterisks mark significant difference
(p ≤ 0.05) of the parameters on different days of treatment when compared to day 0 (before treatment)
measured by a linear mixed-effects model (for temperature) and by robust linear mixed-effects models.
(A) Karnofsky’s score modified for cats. (B) Body weight. (C) Body temperature. (D) Amount of
effusion subjectively evaluated during abdominal/thoracic ultrasound and paracentesis (grades 0
(no fluid) to 4 (massive effusion)).
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Figure 4. Timeline visualizing improvement of clinicopathological parameters throughout the study
course. Figures show average predictive values and 95% confidence intervals of each parameter.
Grey shading marks the reference ranges of the parameters. Red asterisks mark significant difference
(p ≤ 0.05) of the parameters on different days of treatment when compared to day 0 (before treatment)
measured by a linear mixed-effects model (for albumin) and by robust linear mixed-effects models.
(A) Hematocrit. (B) Lymphocyte count. (C) Bilirubin concentration. (D) Total protein concentration.
(E) Albumin concentration. (F) Globulin concentration. (G) Albumin/globulin ratio. (H) Serum
amyloid A (SAA) concentration.
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Figure 5. Feline coronavirus (FCoV) viral RNA loads in blood and effusion samples and serum anti-FCoV antibody
titre measurements. (A) FCoV RNA loads in EDTA anticoagulated blood. (B) FCoV RNA loads in effusions. (C) Serum
anti-FCoV antibody titres. FCoV RNA loads were determined by quantitative reverse transcriptase polymerase chain
reaction (RT-qPCR) (A,B). Antibody titers were determined by indirect immunofluorescence assay (IFA). NT, not tested.
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Figure 6. Viral load in blood and effusion throughout the study course. Figures show visualization of data using nonpara-
metric bootstraps. (A) FCoV RNA loads in EDTA anticoagulated blood. (B) FCoV RNA loads in effusions.
Table 2. Adverse effects of the Xraphconn® treatment, grades of adverse effects, day of first appearance, and respective
symptomatic treatment. 1 Heinz body formation: mild (5–9.9% of red blood cells), moderate (10–25% of red blood cells),
severe (>25% of red blood cells); 2 lymphocytosis: mild (4–7.9 × 109/L), moderate (8–15 × 109/L), severe (>15 × 109/L) 3
was already present on day 0: lymphocytosis: 5/14 cats; eosinophilia: 1/11 4 eosinophilia: mild (0.6–1.9 × 109/L), moderate
(2–10 × 109/L), severe (>10 × 109/L); 5 increased liver enzymes: increased alanine aminotransferase (ALT) activity: mild
(ALT < 200 IU/L), moderate (ALT 200–350 IU/L), severe (ALT >350 IU/L); increased alkaline phosphatase (AP): mild
(AP < 200 IU/L), moderate (AP 200–350 IU/L), severe (AP > 350 IU/L).
Adverse Effect Number of Cats Grade





1/18 moderate 83 S-adenosyl-methionine
14/18 3
4/14 mild 4.5 (2–83) no
Lymphocytosis 2 6/14 moderate 1 (0–28) no
4/14 severe 1 (0–2) no
Eosinophilia 4 11/18 3 11/11 mild 14 (0–28) no
increased liver
enzyme activity 5
8/11 mild 28 (2–83) no
11/18 1/11 moderate 4 no
2/11 severe 4 silymarin





Figure 7. Comparison of the Ultra-High-Performance-Liquid Chromatography Electro-Spray QTRAP
Mass Spectrometry (UHPLC-ESI-QTRAP-MS/MS) spectra of GS-441524 and the active component
of Xraphconn® extracted from the tablet. The compounds in both test solutions were not only
isobaric with [M + H]+ m/z 292.1040, but exhibited identical fragmentation spectra. Mass spectra
were generated at a collision energy of 50 eV with positive ionization using the Multiple Reaction
Monitoring with Information Dependent Acquisition and Enhanced Product Ion (MRM-IDA-EPI)
scan mode. Cps, counts per second.
In NMR, starting from a 2D correlated spectroscopy (2D-COSY) spectrum [48], all
non-exchangeable protons and exchangeable hydroxyl protons of the major compound
in the sample could be assigned. The observed HO-5′ (with COSY cross peaks to both
H-5′ protons) and absence of HO-4′ are characteristic for a furanose ring, while in a
pyranose ring, the opposite is expected. The Heteronuclear Single Quantum Coherence
(HSQC) spectrum [49] provided assignment of carbon signals for CH2 and CH groups
in the molecule, exploiting J-coupling interaction over the proton-carbon chemical bond.
Quaternary carbons were assigned by 3-bond J-coupling interaction between protons and
carbons in the Heteronuclear Multiple Bond Correlation (HMBC) spectrum [50]. The
cross-peak of H-2′ to CN in this HMBC spectrum allowed to unambiguously determine
the position of the cyano-group in the molecule. Obtained 13C chemical shifts (Figure 8)
and patterns of 1H signals (Table S3) correspond to what is reported on GS-441524 [51].
Differences in 1H chemical shifts can be attributed to different sample conditions for pure
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GS-441524 in fully deuterated dimethyl sulfoxide (DMSO-d6) relative to the extract of
Xraphconn® in a DMSO-d6/D2O mixture including salts and other impurities.
 
Figure 8. 13C spectrum of the analyzed sample. Labels refer to the assignment of carbons in the active
component of Xraphconn® depicted above. All signals above 100 ppm belong to the cyano-group
and nucleobase in the identified compound. Some additional signals of uncharacterized impurities
were observed below 80 ppm (indicated with *). Ppm, parts per million.
4. Discussion
In this first prospective controlled treatment trial using an oral antiviral compound
in field cats with FIP, it could be clearly demonstrated that oral treatment with GS-441524
-containing Xraphconn® displays a striking efficacy. All 18 treated cats showed a very
swift response to the treatment with rapid improvement of clinical and clinicopathological
parameters leading to full and relapse-free recovery. Without treatment, virtually all cats
suffering from FIP die, making FIP one of the most lethal diagnoses in the cat population,
instead, the survival rate in the present study for the 18 cats was 100% at the time of
publication. In addition, viral loads decreased in both blood and effusion (where present
and available for RT-qPCR) within a short period of time after treatment initiation, and
none of the cats was blood FCoV RNA-positive after day 14 demonstrating an enormous
response to treatment. Also, antibody titers decreased significantly during therapy. The
in vivo efficacy also mirrors the in vitro data, where GS-441524 containing Xraphconn®
also showed excellent efficacy and induced a rapid decrease of viral loads in FCoV-infected
CRFK cells.
All clinicopathological parameters that are typically altered in cats with FIP improved
significantly within a few days [37]. Typically, total protein, globulin, and bilirubin concen-
trations are elevated in cats with FIP, while albumin concentration, albumin/globulin ratio,
hematocrit, and lymphocyte counts are decreased [52,53]. All these values normalized
within a short period of time with Xraphconn® treatment. Body temperature was elevated
in some cats, but decreased to the reference range during the first few days in the clinic.
However, temperature was generally higher during control visits when compared to the
first days in the clinic, which might be explained by the stress during transportation. Also,
SAA concentrations rapidly and significantly decreased upon treatment in all cats. SAA is
a major acute phase protein in cats, and SAA expression has been shown to be increased
in cats with FIP, indicating the presence of a severe inflammatory response [54–57]. The
marked reduction in SAA concentrations in response to treatment reflects the clinical
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efficacy of the multi-component drug Xraphconn® and suggests a remarkable attenuation
of the hyperinflammatory response seen in cats with FIP.
Structural chemical analysis to identify the active components of the multi-compound
drug by using mass spectrometry and NMR identified GS-441524 as the single adenine
C-nucleoside ribose analogue extracted from Xraphconn®. No other similar nucleoside
analogues were detected, although it cannot be excluded that there might be additional
active ingredients present in Xraphconn®.
Although a very good efficacy of GS-441524 upon subcutaneous administration has
been demonstrated in an experimental study and in cats in the field before [25,28], the
present study demonstrated an even higher efficacy, as all of the 18 treated cats were
apparently cured when the drug was administered orally. There are several potential
reasons for these favorable results. First, additional substances to the GS-441524, such as
herbal preparations, in the multi-component drug Xraphconn® might increase efficacy with
some of these substances exhibiting synergistic effects. Second, only cats with a confirmed
diagnosis or at least very likely diagnosis of FIP were included in the present study and
therefore, there was little chance that cats with other severe diseases were mistakenly
treated with the drug. Third, all cats received intensive medical care 24/7 as well as
symptomatic treatment, especially during the first critical seven days, including in-depth
diagnostic procedures and individualized supportive treatment in a highly specialized
university hospital.
This is the first time that oral (instead of subcutaneous) treatment was applied to
cats with FIP in a controlled study. In the past, oral treatment was used successfully in
a case report in one cat with neurological FIP [26]. The study of Jones and coworkers
(2021) “unlicensed GS-441524-like antiviral therapy can be effective for at-home treatment
of feline infectious peritonitis” [34] was an online survey study that drew its findings from
testimonials from private owners who had provided independent and non-standardized
as well as non-supervised therapy to their cats. Similarly, the study of Yin and coworkers
(2021) “a retrospective study of clinical and laboratory features and treatment on cats highly
suspected of feline infectious peritonitis in Wuhan, China” [35], was a retrospective study
and did not have any prospective aspect. Thus, these studies were not prospective and
therefore are not comparable to the current study.
Oral treatment has several advantages. In previous studies with subcutaneous injec-
tions of GS-441524, more than half of the cats developed injection site reactions [25]. In
such inflammatory reactions could trigger development of FISS. In addition, handling of
subcutaneous injections is difficult and challenging for owners and can be very painful
for the cats causing injection reactions. In the present study, all 18 cats treated orally
remained cooperative throughout the entire treatment period and the owners were able to
successfully administer the tablets.
The study protocol set a fixed dose for each participating cat (10 mg/kg for cats with
neurological/ocular signs and 5 mg/kg for cats without neurological/ocular signs). The
package insert specified the concentration of the active component within the tablets and
the dosages applied to cats were based on this information and on the previous published
studies [24,28]. However, the exact amount of GS-441524 within the Xraphconn® tablets
was not verified in the present study, but all cats were apparently cured and no major
adverse effects were reported, it has to be assumed that the dose given in the package
insert was correct. Individualized dosing of cats, as sometimes recommended by social
media groups, based on laboratory parameters, such as globulin concentrations, did not
appear necessary or indicated in the current study. In addition, a standardized additional
symptomatic therapy for each cat as advised by social media groups, e.g., tablets for liver
protection, was not necessary. The present study clearly demonstrates the importance of
adapting symptomatic treatment according to the problems and needs of the individual
cats. Unrelated problems can occur, such as a renal mineralization in one of the cats in the
current study, which would not have been detected if owners had treated their cats at home
without veterinary supervision, which can lead to significant problems, independent of
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FIP, without adequate diagnosis and therapy. Thus, FIP treatment should not be left in the
hands of owners alone, and legal approval of the drug in veterinary medicine is urgently
needed. Whether a shorter treatment duration would be possible and successful, and to
aid in the reduction of high costs, remains to be determined. In the present study, no cat
was viremic by day 14 after starting treatment and viral levels in effusions were similarly
reduced. It might therefore be interesting to investigate the efficacy of a shorter treatment
period in a well-controlled study.
Two cats had to be excluded from the study due to their severe moribund condition.
In the present study, cats were only included after extensive efforts were made to obtain a
diagnosis of FIP. This was performed by applying an individualized multi-step diagnostic
approach, including extensive physical examination, basic clinicopathological data, diag-
nostic imaging, and methods for direct virus detection (immunohistochemistry and/or
spike gene mutation analysis with RT-PCR). A diagnosis of FIP cannot be obtained easily by
one diagnostic test, since clinical and pathological abnormalities and imaging findings are
not pathognomonic, and the detection of viral RNA by RT-PCR with or without mutation
analysis, is not diagnostic for FIP [36]. Thus, a multimodal diagnostic approach is highly
advisable; however, this is time-consuming, and disease progression in the meantime might
preclude treatment success in some cats with severe disease. Nevertheless, in the face of
cost and emergence of viral drug resistance, the aim should still be to be as confident as
possible that a cat is truly suffering from FIP before starting antiviral treatment, and this
can only be done by veterinarians, again highlighting the importance of having veterinary
involvement in FIP diagnosis and treatment.
The viral RNA loads in accessible abdominal or thoracic effusions decreased in all cats
over the study period, and looking at the blood viral RNA loads, it is assumed that viral
RNA was also cleared from the thoracic and/or abdominal compartments. The Xraphconn®
treatment was therefore beneficial in reducing viral RNA loads in effusions and blood and
cured abdominal and/or thoracic effusions in cats with FIP. A remarkably high percentage
of cats with FIP in this study (83%) were viral RNA-positive in blood upon entering the
study. In other studies in cats with confirmed FIP, detection of viral RNA in blood was
rather a rare event [53,58–61]. Thus, the notion that viremia will likely usually be over
by the time clinical signs of FIP appear [42], has to be reconsidered in view of the current
data. Most cats in the present study with FIP had remarkably high antibody titers, which
decreased in most but not all cats over time.
The adverse effects reported with the Xraphconn® treatment in the present study were
considered to be acceptable and not serious, and treatment did not need to be discontinued
in any of the cats. No gastrointestinal signs were caused by oral administration. Previous
studies using GS-441524 have mainly reported adverse effects related to subcutaneous
injection (e.g., pain reactions, superficial skin lesions, skin ulceration). A decrease in hema-
tocrit, total protein, and albumin during the first days of treatment in the clinic likely
occurred due to blood sampling and might be a dilutional effect due to fluid therapy, but
was fully reversible. The most pronounced adverse effect seen in the present study was a
lymphocytosis that occurred in 14/18 cats. Significant abnormalities in hematological pa-
rameters have not been reported as adverse effects in association with GS-441524 treatment
in field cats so far [24–26,28]; however, a marked increase in the lymphocyte count was also
seen after treatment of cats with experimental FIP [28]. Lymphocytosis could have been
caused by excitement to which cats are very sensitive, or by antigen stimulation. While
younger cats generally have higher lymphocyte counts, the changes were too pronounced
to be explained only by young age. The changes observed for lymphocyte counts in re-
sponse to treatment appear to be of particular interest. Though this study did not aim to
characterize the host immune response in detail, it is interesting to observe that mild to
moderate lymphocytosis was seen in >75% of cats following treatment initiation, while
SAA concentrations displayed a rapid and sustainable decline in all participating animals.
One cat developed a massive lymphocytosis on day 83 (40.7 × 109/L) and PARR-based
exclusion of clonality and thus malignancy suggested a reactive lymphoid population. To
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some extent, these lymphocyte responses remind the clinician of features seen in Immune-
Reconstitution Inflammatory Syndrome (IRIS) [62]. One could speculate that cytokines
produced by monocytes upon FCoV infection could cause both a reduction of lymphocytes
and an impaired immune response to FCoV. Lymphopenia is a common feature [53,63]
and negative prognostic factor [53] in cats with FIP, caused by increased apoptosis of
B and T cells induced by tumor necrosis factor alpha expression [64–68]. As a consequence,
a rebound in the immune response could occur after the cytokine effect fades. Additionally,
FCoV-infected cats without FIP were shown to exhibit B and T cell hyperplasia [66,69,70]
and increased numbers of circulating T cells [63]. It would thus be of particular interest to
further characterize these immunologic features and the cellular immune response against
FCoV before and after treatment.
Eosinophilia was noted as another effect of the Xraphconn® treatment in this study.
Parasitic infestation was ruled out in most cats, and there was no obvious reason for the
eosinophilia. Eosinophil counts were not specifically evaluated in previous studies [24,25,28].
Interestingly, an increase in the eosinophil count has also been found in human pa-
tients recovering from COVID-19 and has been proposed as a marker for a favorable
outcome [71–73]. Whether there was a hypersensitivity reaction resulting in eosinophilia
due to treatment in the current study needs to be clarified in further research.
One cat developed mild Heinz body anemia on the last day of therapy. Heinz body
formation occurs as a result of oxidative damage to hemoglobin and can result in hemol-
ysis [74]. In cats, increased Heinz body formation has previously been shown to be
associated with the administration of certain drugs and components, such as propofol [75],
acetaminophen [76], or propylene glycol [77]. Therefore, it seems possible that there is an
association between the repeated administration of Xraphconn® and Heinz body formation
in this cat. Further studies should include the quantification of Heinz body formation
during antiviral treatment in order to clarify a possible causal relationship.
An increase of liver enzyme activity was noted in some cats, but was primarily of
a mild to moderate scale. Since GS-441524 is metabolized in the liver, this metabolism
could possibly lead to an increased metabolic rate with increased liver enzyme activity.
Increases in liver enzyme activity have been reported as adverse effects with this multi-
component compound treatment before in an unpublished observation [78]. In the present
study, renal toxicity did not occur, which is in agreement with one previously published
study [25]. Symmetric dimethylarginine values, considered to be a very sensitive parameter
for kidney function, remained within the reference range throughout the treatment. Only
one cat with thoracal and abdominal effusion had an SDMA of 18 µmol/L (reference
range 0–18 µmol/L) on day 0 before treatment, likely due to impaired perfusion of the
kidneys secondary to FIP, but values normalized after treatment was started. Another
single cat had renal azotemia and increased SDMA values, which were already present at
inclusion into the study. Therefore, it was reasonable to suspect that renal changes before
entering the study were caused by FIP. However, in the further course of the study, the
cat developed unilateral renal mineralization and mild pyelectasia, which progressed to
ureteral obstruction, most likely caused by a ureterolith, after the end of treatment. The
cat did not show overt clinical signs related to kidney disease except for the development
of a very small amount of ascites. Given that azotemia was already present before the
start of Xraphconn® treatment, it seems unlikely that the renal changes represent adverse
effects, but rather were the consequence of progressive kidney disease unrelated to the
Xraphconn® treatment. In a previous study [25], one cat treated with GS-441524 showed
a progressive increase in urea and sudden rise in SDMA concentration during repeated
rounds of treatment and as a precaution, it was decided to stop treatment. However, urine
specific gravity measurement was not reported in that study, so the presence of renal
azotemia, as compared to prerenal azotemia, could not be confirmed. Additionally, urea
and SDMA concentrations returned to normal after discontinuation of treatment [25]. In a
case report of a cat with FIP treated with the same multi-component compound as in the
current study, an increased SDMA was noted during treatment, which normalized after
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drug discontinuation, although it was not confirmed whether this was as a consequence of
antiviral treatment [26].
The question arises as to whether remdesivir, which is licensed for the treatment of
humans with severe COVID-19, could be useful for treatment of FIP in cats, Remdesivir
has been used by veterinarians in Australia to treat cats with FIP, although published
studies are not yet available. GS-44152 is the main metabolite of remdesivir, a prodrug of
the nucleoside analogue, which has been used with limited success in patients with acute
COVID-19 [29,79]. Remdesivir needs to be applied by injection since it has no acceptable
oral bioavailability. In contrast, oral admission of GS-441524 was shown to be effective in
mice against COVID-19 [29,80]. Another advantage of GS-441524 over remdesivir appears
to be its reduced liver toxicity allowing dose escalation to ensure effective treatment
of systemic coronavirus infections [81]; GS-441524 is directly converted into the active
nucleoside triphosphate in liver and lung tissue.
The results of the present study can also be viewed from a broader perspective. In
the context of the COVID-19 pandemic, pediatricians worldwide have been confronted
with a new disease in children, a syndrome associated with SARS-CoV-2 infection and
referred to as multisystem inflammatory syndrome in children (MIS-C). When comparing
clinical features of FIP with MIS-C, remarkable parallels can be found [5,6]. MIS-C, like
FIP, is a hyperinflammatory immune response, primarily seen in the children [5,6]. Af-
fected children initially show often only gastrointestinal signs, while in the course of the
disease, further symptoms appear, such as persistent fever, ascites, pleural, and pericardial
effusion [5,82,83], all of which are also commonly found in cats with FIP. Therefore, FIP
might provide a useful natural model for insights into the pathogenesis and immunology
of MIS-C, but also into potential treatment options pending further studies [84]. Finally,
studying FIP in cats and the host response to treatment could serve as an interesting
natural model for further elucidating features of MIS-C in children. The model could
provide critical insights into pathophysiology and immunology of these similar clinical
entities and might also help to explore new potential treatment options for this severe
SARS-CoV-2-associated disease.
The major limitation of this study was that no untreated control group was included.
However, leaving cats with FIP untreated is not justifiable for ethical reasons, and the short
median survival time in cats with FIP of eight to nine days clearly has been demonstrated
before [9,20]. Thus, without treatment, almost all cats would die within a very short time
frame. Another limitation was that the potential efficacy of the additional components in
the tablets (other than GS-441524) was not determined in the present study, and measuring
any antiviral efficacy of the other components, once successfully identified and purified,
would be an interesting additional approach in the future. Due to the oral application of the
treatment, cats in a moribund condition could not be included in the study. The two cats
that were excluded from the study were in a severely moribund end-stage condition. An
oral drug would likely not have had any effect in such a condition, due to the low metabolic
rate and the fact that oral medications are hardly absorbed from a likely inactive intestinal
tract. Therefore, the cats were not included in the study and instead euthanized for humane
reasons. Also, the small sample size of the current study is an additional limitation.
5. Conclusions
In conclusion, this study is the first prospective treatment trial clearly demonstrating
that cats suffering from this tragic and fatal disease can be cured with oral treatment.
Unfortunately, the drug is not currently legally available for veterinary use in many
countries, forcing well-meaning owners to self-diagnose and treat their cats based on
judgment of non-veterinary lay people and social media groups. Thus, there is an urgent
need for respective official bodies and industry to work towards a swift licensing process
of the drug so that it can be legally used by veterinary experts to offer supervised treatment
to cats suffering from FIP.
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difference (p ≤ 0.05) of the parameters on different days of treatment when compared to day 0 (before
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